High expression level of EDIL3 in HCC predicts poor prognosis of HCC patients

Table 1 Relation between epidermal growth factor-like repeats and discoidin I-like domains 3 expression in hepatocellular carcinoma and clinicopathological features of hepatocellular carcinoma patients

Clinicopathologic features (n)	Low EDIL3 (total score < 4) n = 52	High EDIL3 (total score ≥ 4) n = 49	P value
Age (yr)			0.889
< 60 (57)	29	28
≥ 60 (44)	23	21
Gender			0.648
Male (87)	44	43
Female (14)	8	6
Tumor size (cm)			0.491
< 5 (26)	16	10
5-10 (58)	28	30
> 10 (17)	8	9
Histological differentiation			0.379
Well (17)	9	8
Moderate (63)	35	28
Poor (21)	8	13
Liver cirrhosis			0.617
Yes (50)	27	23
No (51)	25	26
Metastasis			0.202
Yes (15)	10	5
No (86)	42	44
Recurrence			0.817
Yes (38)	19	19
No (63)	33	30
HBSAg status			0.527
Positive (90)	45	45
Negative (11)	7	4
Serum AFP			0.707
Positive (62)	31	31
Negative (39)	21	18

EDIL3: Epidermal growth factor-like repeats and discoidin I-like domains 3; HBSAg: Hepatitis B surface antigen; AFP: α-fetoprotein.

Table 2 Univariate and multivariate analysis showing the overall survival rate for hepatocellular carcinoma patients

Variables	Univariate analysis			Multivariate analysis
	HR	95% CI	P value	HR	95% CI	P value
EDIL3	2.019	1.163-3.504	0.013	1.978	1.139-3.435	0.015
Gender	0.658	0.283-1.529	0.330
Age	0.817	0.487-1.370	0.443
Tumor size	1.662	1.133-2.437	0.009	1.492	0.980-2.270	0.062
Histologic grade	1.304	0.866-1.963	0.204
Cirrhosis	0.683	0.410-1.139	0.144
HBsAg status	1.244	0.565-2.738	0.588
Serum AFP	1.592	0.923-2.744	0.094
Metastasis	1.407	0.731-2.707	0.307
Recurrence	1.349	0.804-2.263	0.257

HR: Hazard ratio; CI: Confidence interval; EDIL3: Epidermal growth factor-like repeats and discoidin I-like domains 3; HBSAg: Hepatitis B surface antigen; AFP: α-fetoprotein.